scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0960-8966(02)00213-4 |
P698 | PubMed publication ID | 12565916 |
P50 | author | Francesco Muntoni | Q29645259 |
P2093 | author name string | Bourke JP | |
Bushby K | |||
P2860 | cites work | Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy | Q22009039 |
Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy | Q24317622 | ||
Unusual type of benign x-linked muscular dystrophy | Q24519418 | ||
Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan | Q24535942 | ||
Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. | Q24539152 | ||
Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease | Q28139053 | ||
Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy? | Q28353993 | ||
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats | Q32055195 | ||
Cardiomyopathy may be the only clinical manifestation in female carriers of Duchenne muscular dystrophy | Q72586556 | ||
Cardiomyopathy in duchenne, becker, and sarcoglycanopathies: a role for coronary dysfunction? | Q73066157 | ||
Pathogenesis of inherited forms of dilated cardiomyopathy | Q73223944 | ||
Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy | Q73226910 | ||
Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls | Q73637225 | ||
Cardiac abnormalities and cytosine-thymine-guanine trinucleotide repeats in myotonic dystrophy | Q73739637 | ||
The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach | Q73739715 | ||
Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period | Q73949073 | ||
Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length | Q74176906 | ||
Right ventricular MR abnormalities in myotonic dystrophy and relationship with intracardiac electrophysiologic test findings: initial results | Q74390304 | ||
Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy | Q74529487 | ||
Steroids in muscular dystrophy: where do we stand? | Q77131915 | ||
Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C | Q77346768 | ||
60th ENMC International Workshop: non X-linked Emery-Dreifuss Muscular Dystrophy 5-7 June 1998, Naarden, The Netherlands | Q77376208 | ||
Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy | Q77568415 | ||
Clinical characteristics of sudden death victims in heritable (chromosome 1p1-1q1) conduction and myocardial disease | Q77579194 | ||
Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy | Q77808613 | ||
MR Imaging of the heart with cine true fast imaging with steady-state precession: influence of spatial and temporal resolutions on left ventricular functional parameters | Q77870953 | ||
Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy | Q78005705 | ||
Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis | Q78039379 | ||
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation | Q78616932 | ||
Myotonic heart disease: a clinical follow-up | Q33158068 | ||
Emerin and cardiomyopathy in Emery-Dreifuss muscular dystrophy | Q33603986 | ||
Cardiac involvement in congenital myotonic dystrophy | Q33610382 | ||
The natural history of congenital myotonic dystrophy: mortality and long term clinical aspects | Q33623147 | ||
The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms | Q33724091 | ||
Major beta blocker mortality trials in chronic heart failure: a critical review | Q33780871 | ||
The cardiomyopathies: an overview | Q33866492 | ||
Electrocardiographic findings in myotonic dystrophy | Q34117784 | ||
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators | Q34539986 | ||
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group | Q34718800 | ||
The heart in limb girdle muscular dystrophy. | Q35366393 | ||
Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series | Q35373093 | ||
Emery-Dreifuss muscular dystrophy: report of five cases in a family and review of the literature | Q39792724 | ||
Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy | Q41004237 | ||
Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement | Q44395107 | ||
Relation of cardiac abnormalities and CTG-repeat size in myotonic dystrophy | Q47210873 | ||
Cardioprotection for Duchenne's muscular dystrophy | Q48224419 | ||
Left ventricular myocardial function in myotonic dystrophy. | Q51059337 | ||
Ventricular late potentials in myotonic dystrophy. | Q52440069 | ||
Systemic and regional hemodynamic effects of perindopril in congestive heart failure | Q54327761 | ||
Cardiac involvement in patients with myotonic dystrophy: characteristic features of magnetic resonance imaging | Q57085849 | ||
Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene | Q57640076 | ||
Evaluation of cardiac and respiratory involvement in sarcoglycanopathies | Q58052185 | ||
Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies | Q58052218 | ||
Evaluation of the cardiomyopathy in becker muscular dystrophy | Q58052228 | ||
Dilated cardiomyopathy requiring cardiac transplantation as initial manifestation of Xp21 Becker type muscular dystrophy | Q58911533 | ||
Natural history of cardiac involvement in myotonic dystrophy: Correlation with CTG repeats | Q60050798 | ||
A mutation in the X-linked Emery–Dreifuss muscular dystrophy gene in a patient affected with conduction cardiomyopathy | Q61978469 | ||
High Incidence of Sudden Death with Conduction System and Myocardial Disease Due to Lamins A and C Gene Mutation | Q63531545 | ||
Cardiac involvement in Becker muscular dystrophy. | Q64896809 | ||
Sequence of cardiac changes in Duchenne muscular dystrophy | Q67260188 | ||
Familial Congenital Sinus Rhythm Anomalies: Clinical and Pathological Correlations | Q67463881 | ||
The heart in Duchenne muscular dystrophy: a non-invasive longitudinal study | Q67554298 | ||
The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy | Q68122875 | ||
Permanent paralysis of the atrium in a patient with facioscapulohumeral muscular dystrophy | Q69503608 | ||
Cerebral embolization in two young patients with fascioscapulohumeral muscular dystrophy and atrial dysrhythmias | Q69714178 | ||
Discrepancy between systolic and diastolic dysfunction of the left ventricle in patients with Duchenne muscular dystrophy | Q70754430 | ||
Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy | Q71127157 | ||
Echocardiographic evaluation of left ventricular function in Duchenne's muscular dystrophy | Q71286957 | ||
Cardiac dysfunction with Becker muscular dystrophy | Q71517866 | ||
Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy | Q71822781 | ||
Cardiac involvement in facio-scapulo-humeral muscular dystrophy: a family study using Thallium-201 single-photon-emission-computed tomography | Q71971083 | ||
Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: an echocardiographic study | Q72279706 | ||
P433 | issue | 2 | |
P921 | main subject | Netherlands | Q55 |
muscular dystrophy | Q1137767 | ||
P304 | page(s) | 166-172 | |
P577 | publication date | 2003-02-01 | |
P1433 | published in | Neuromuscular Disorders | Q1981326 |
P1476 | title | 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. | |
P478 | volume | 13 |
Q36266919 | A case of Becker muscular dystrophy with early manifestation of cardiomyopathy |
Q87157531 | Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta Blocker Treatment in mdx Mice |
Q36877691 | Ambulatory Monitoring and Arrhythmic Outcomes in Pediatric and Adolescent Patients With Duchenne Muscular Dystrophy |
Q36466464 | An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy |
Q33680612 | Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy |
Q45242479 | Autosomal dominant limb-girdle muscular dystrophy associated with conduction defects (LGMD1B): a description of 8 new families with the LMNA gene mutations |
Q34600310 | Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy |
Q39010745 | Can Human Pluripotent Stem Cell-Derived Cardiomyocytes Advance Understanding of Muscular Dystrophies? |
Q30487626 | Cardiac assessment of patients with late stage Duchenne muscular dystrophy |
Q43628283 | Cardiac involvement determines the prognosis of Duchenne muscular dystrophy |
Q43836668 | Cardiac involvement in Dutch patients with sarcoglycanopathy: a cross-sectional cohort and follow-up study |
Q50052366 | Cardiac involvement in the muscular dystrophies |
Q38204281 | Cardiac management of ventilator-assisted individuals with Duchenne muscular dystrophy |
Q36398766 | Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders |
Q42833726 | Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne's muscular dystrophy: relationship to clinical outcome. |
Q37639933 | Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics |
Q37889770 | Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions |
Q37312201 | Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry |
Q57642759 | Clinical and muscle biopsy findings in Norwegian paediatric patients with limb girdle muscular dystrophy 2I |
Q38267714 | Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions |
Q37552615 | Consensus statement on standard of care for congenital muscular dystrophies |
Q36069707 | Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy |
Q43270760 | Contiguous gene deletion syndrome in a female with ornithine transcarbamylase deficiency |
Q33844719 | Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy |
Q24185788 | Corticosteroids for the treatment of Duchenne muscular dystrophy |
Q87425283 | Current treatment and management of dystrophinopathies |
Q36949803 | Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. |
Q28082625 | Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy |
Q88689556 | DMD mutation and LTBP4 haplotype do not predict onset of left ventricular dysfunction in Duchenne muscular dystrophy |
Q45281605 | Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. |
Q37105210 | Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy |
Q37640907 | Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management |
Q37640910 | Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care |
Q36982543 | Diagnostic utility of cardiac magnetic resonance for detection of cardiac involvement in female carriers of Duchenne muscular dystrophy |
Q41822348 | Diastolic dysfunction precedes hypoxia-induced mortality in dystrophic mice |
Q87396216 | Dilated cardiomyopathy |
Q42350965 | Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle |
Q43076294 | Duchenne muscular dystrophy: Canadian paediatric neuromuscular physicians survey. |
Q28067793 | Duchenne muscular dystrophy: the management of scoliosis |
Q44607177 | Duchenne/Becker muscular dystrophy in the family: have potential carriers been tested at a molecular level? |
Q35606737 | Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials |
Q37367994 | ERK1/2 directly acts on CTGF/CCN2 expression to mediate myocardial fibrosis in cardiomyopathy caused by mutations in the lamin A/C gene |
Q82296972 | Early detection of cardiomyopathy in Duchenne muscular dystrophy, is there a role for MRI? |
Q42855263 | Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. |
Q56900219 | Echocardiographic and Electrocardiographic Findings of Cardiomyopathy in Duchenne and Becker?Kiener Muscular Dystrophies |
Q99240518 | Efficacy and safety of ropivacaine HCl in peribulbar anaesthesia for cataract surgery in patients with myotonic dystrophy type 1 |
Q24670706 | Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy |
Q49164127 | Evaluation of cardiac functions in children with Duchenne Muscular Dystrophy: A prospective case-control study |
Q48621814 | Evaluation of the North Star Ambulatory Assessment scale and cardiac abnormalities in ambulant boys with Duchenne muscular dystrophy |
Q34508301 | Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease |
Q36728102 | Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice |
Q38085610 | Genetic and clinical characteristics of skeletal and cardiac muscle in patients with lamin A/C gene mutations |
Q38125766 | Genetics in dilated cardiomyopathy |
Q24242199 | Glucocorticoid corticosteroids for Duchenne muscular dystrophy |
Q24247197 | Glucocorticoid corticosteroids for Duchenne muscular dystrophy |
Q33697703 | Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. |
Q41766907 | Heterogeneous abnormalities of in-vivo left ventricular calcium influx and function in mouse models of muscular dystrophy cardiomyopathy |
Q36895785 | Hypoxia-induced cardiac injury in dystrophic mice |
Q33970356 | Identification of de novo mutations of Duchénnè/Becker muscular dystrophies in southern Spain. |
Q45868920 | Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. |
Q54399356 | Increased connective tissue growth factor associated with cardiac fibrosis in the mdx mouse model of dystrophic cardiomyopathy. |
Q36861720 | Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy. |
Q42950227 | Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy |
Q35582781 | Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy |
Q57390065 | Limb Girdle Muscular Dystrophies |
Q54487655 | Manifesting carriage of a Duchenne muscular dystrophy mutation: an unusual cause of impaired lung function in CF. |
Q35122156 | Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila |
Q86291937 | Muscular dystrophies |
Q33917072 | Myocardial atrophy in children with mitochondrial disease and Duchenne muscular dystrophy. |
Q37278457 | Myocardial late gadolinium enhancement is associated with clinical presentation in Duchenne muscular dystrophy carriers |
Q36925658 | Myostatin does not regulate cardiac hypertrophy or fibrosis |
Q64884115 | Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy. |
Q41955267 | Nestin expression in end-stage disease in dystrophin-deficient heart: implications for regeneration from endogenous cardiac stem cells |
Q36226880 | Neurology and orthopaedics |
Q37910906 | Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy |
Q47747088 | Prenatal diagnosis of Duchenne and Becker muscular dystrophies: Underestimated problem of the secondary prevention of monogenetic disorders |
Q30626615 | Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice |
Q27348818 | Quality improvement in neurology: muscular dystrophy quality measures |
Q46527029 | Rapidly progressive heart failure requiring transplantation in muscular dystrophy: a need for frequent screening |
Q42754311 | Recovery of systolic dysfunction in duchenne muscular dystrophy due to the point mutation c.4213C>T. |
Q48005629 | Results of Duchenne muscular dystrophy family screening in practice: leaks rather than cascades? |
Q38368957 | Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children |
Q24621454 | Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy |
Q34279254 | Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. |
Q36288840 | Structural and functional cardiac changes in myotonic dystrophy type 1: a cardiovascular magnetic resonance study |
Q45384428 | Subepicardial dysfunction leads to global left ventricular systolic impairment in patients with limb girdle muscular dystrophy 2I. |
Q37240478 | Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts |
Q36351131 | The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease |
Q51641338 | The screening for X-linked Emery-Dreifuss muscular dystrophy amongst young patients with idiopathic heart conduction system disease treated by a pacemaker implant. |
Q37329558 | Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies |
Q36304335 | Therapy insight: cardiovascular complications associated with muscular dystrophies |
Q36227105 | Towards an integrative approach to the management of myotonic dystrophy type 1 |
Q38178061 | Treatment of dystrophin cardiomyopathies |
Q82576866 | Treatment of the heart in Duchenne muscular dystrophy |
Q35820608 | Unusual respiratory manifestations in two young adults with Duchenne muscular dystrophy |
Q33408844 | Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy |